{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.12","value":"21.5"},{"groupId":"OG001","spread":"14.3","value":"26.3"},{"groupId":"OG002","spread":"32.1","value":"33.6"},{"groupId":"OG003","spread":"10.4","value":"32.1"},{"groupId":"OG004","spread":"14.1","value":"34.1"},{"groupId":"OG005","spread":"10.9","value":"23.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"58"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"142"}],"units":"Participants"}],"title":"After the First Dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.3","value":"69.9"},{"groupId":"OG001","spread":"29.8","value":"67.5"},{"groupId":"OG002","spread":"28.3","value":"62.7"},{"groupId":"OG003","spread":"24.1","value":"62.5"},{"groupId":"OG004","spread":"22.9","value":"65.9"},{"groupId":"OG005","spread":"20.1","value":"53.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"44"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"106"}],"units":"Participants"}],"title":"At Steady State"}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"58"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"143"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants received cemiplimab 3 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks (Q2W) during each 8-week treatment cycle, for up to 96 weeks (12 cycles).","id":"OG000","title":"Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W"},{"description":"Participants received cemiplimab 3 mg/kg IV Q2W during each 8-week treatment cycle, for up to 96 weeks (12 cycles).","id":"OG001","title":"Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W"},{"description":"Participants received cemiplimab 350 mg IV every 3 weeks (Q3W) during each 9-week treatment cycle, for up to 54 weeks (6 cycles).","id":"OG002","title":"Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W"},{"description":"Participants received cemiplimab 600 mg IV every 4 weeks (Q4W) during each 8-week treatment cycle, for up to 48 weeks (6 cycles).","id":"OG003","title":"Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W"},{"description":"Participants received a single 438 mg subcutaneous (SC) dose of cemiplimab followed by cemiplimab 350 mg IV Q3W during each 9-week treatment cycle, for up to 54 weeks (6 cycles).","id":"OG004","title":"Group 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3W"},{"description":"Participants received cemiplimab 350 mg IV Q3W during each 9-week treatment cycle, for up to 108 weeks (12 cycles).","id":"OG005","title":"Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W"}],"paramType":"MEAN","populationDescription":"The PK analysis set included all participants who had received cemiplimab and had at least 1 qualified (non-missing) post-baseline measurement of cemiplimab concentration in serum. Here, \"Overall number of participants analyzed\" is the number of participants evaluable for this outcome measure, and \"Number analyzed\" is the number of participants evaluable at each specified point.","reportingStatus":"POSTED","timeFrame":"Up to approximately 43 months","title":"Trough Concentration (Ctrough) of Cemiplimab","type":"SECONDARY","unitOfMeasure":"mg/L"}